A Comparison of Mirtazapine and Paroxetine for the Treatment of Patients with Posttraumatic Stress Disorder: A Randomized Open-label Trial
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Objective: The present study compared the efficacy and tolerability of treatment with mirtazapine and paroxetine for patients with posttraumatic stress disorder (PTSD). Methods: Forty subjects with PTSD were randomly assigned to the mirtazapine or paroxetine treatment group. The drugs were administered for 8 weeks with a flexible dosing schedule, and the clinician-administered PTSD scale (CAPS-2) was used to evaluate clinical symptoms at the baseline and at weeks 2, 4, and 8. Treatment responsiveness was defined as a ≥30% decrease in the CAPS-2 total score from the baseline. Results: After 8 weeks, a significant decrease in the mean CAPS-2 score compared with the baseline was observed in both treatment groups. However, the mean change in the CAPS-2 score did not differ between the treatment groups at any point over the study period. At 8 weeks, the response rate was 70% for the mirtazapine group and 85% for the paroxetine group. No serious adverse reaction was noted in either treatment group, and both drugs were well tolerated. Conclusion: The results of this study support a possible role for mirtazapine in the treatment of PTSD symptoms. To reach a more definite conclusion, larger double-blind, placebo-controlled, head-to-head comparison studies are needed.
Abstract
Objective: The present study compared the efficacy and tolerability of treatment with mirtazapine and paroxetine for patients with posttraumatic stress disorder (PTSD). Methods: Forty subjects with PTSD were randomly assigned to the mirtazapine or paroxetine treatment group. The drugs were administered for 8 weeks with a flexible dosing schedule, and the clinician-administered PTSD scale (CAPS-2) was used to evaluate clinical symptoms at the baseline and at weeks 2, 4, and 8. Treatment responsiveness was defined as a ≥30% decrease in the CAPS-2 total score from the baseline. Results: After 8 weeks, a significant decrease in the mean CAPS-2 score compared with the baseline was observed in both treatment groups. However, the mean change in the CAPS-2 score did not differ between the treatment groups at any point over the study period. At 8 weeks, the response rate was 70% for the mirtazapine group and 85% for the paroxetine group. No serious adverse reaction was noted in either treatment group, and both drugs were well tolerated. Conclusion: The results of this study support a possible role for mirtazapine in the treatment of PTSD symptoms. To reach a more definite conclusion, larger double-blind, placebo-controlled, head-to-head comparison studies are needed.
참고문헌 (23)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders. 4th ed" (1994), American Psychiatric Association
- Marshall RD, "Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study", Am J Psychiatry, 158, pp.1982~1988 (2001)
- Tucker P, "Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial", J Clin Psychiatry, 62, pp.860~868 (2001)
- Brady K, "Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial", JAMA, 283, pp.1837~1844 (2000)
- Davidson JR, "Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder", Arch Gen Psychiatry, 58, pp.485~492 (2001)
- Davidson JR, "Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial", Biol Psychiatry, 53, pp.188~191 (2003)
- de Boer T, "The pharmacologic profile of mirtazapine", J Clin Psychiatry, 57(4), pp.19~25 (1996)
- Quitkin FM, "Does mirtazapine have a more rapid onset than SSRIs?", J Clin Psychiatry, 62, pp.358~361 (2001)
- Watanabe N, "Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis", J Clin Psychiatry, 69, pp.1404~1415 (2008)
- Bahk WM, "Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study", Hum Psychopharmacol, 17, pp.341~344 (2002)
- Connor KM, "A pilot study of mirtazapine in post-traumatic stress disorder", Int Clin Psychopharmacol, 14, pp.29~31 (1999)
- Kim W, "The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy", Psychiatry Clin Neurosci, 59, pp.743~747 (2005)
- Chung MY, "Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial", Hum Psychopharmacol, 19, pp.489~494 (2004)
- First MB, "Structural Clinical Interview for DSM-IV-Clinician Version (SCID-CV)" (1997), American Psychiatric Press
- Blake DD, "The development of a clinicianadministered PTSD Scale", J Trauma Stress, 8, pp.75~90 (1995)
- Beck AT, "Manual for the beck depression inventory II (BDI-II)" (1996), Psychology Corporation
- Guy W, "ECDEU assessment manual for psychopharmacology. US department of health, education, and welfare publication (ADM)", National Institute of Mental Health, ~ (1976)
- Levine J, "SAFTEE: a technique for the systematic assessment of side effects in clinical trials", Psychopharmacol Bull, 22, pp.343~381 (1986)
- Behnke K, "Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study", J Clin Psychopharmacol, 23, pp.358~364 (2003)
- Benkert O, "Mirtazapine compared with paroxetine in major depression", J Clin Psychiatry, 61, pp.656~663 (2000)
- Marshall RD, "An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder", J Clin Psychopharmacol, 18, pp.10~18 (1998)
- Roth S, "Complex PTSD in victims exposed to sexual and physical abuse: results from the DSM-IV Field Trial for Posttraumatic Stress Disorder", J Trauma Stress, 10, pp.539~555 (1997)
- Deering CG, "Unique patterns of comorbidity in posttraumatic stress disorder from different sources of trauma", Compr Psychiatry, 37, pp.336~346 (1996)